Patient reported outcomes (PRO) and observer (caregiver) reported outcomes (ObsRO) are important determinants of drug efficacy, safety, and quality-of-life (QoL) in Alzheimer's disease (AD) patients. The inherent cognitive impairment incurred by AD patients often necessitates the collection of ObsROs, especially as the disease progresses. Therefore, determining which PROs and ObsROs accurately reflect transitions in disease status in AD and dementia patients is critical. A meta-review was conducted using electronic databases, including PubMed, to determine the most commonly used outcome measures in AD, whether QoL PROs were effective in AD patients, and whether caregiver assessments adequately depicted patient QoL/disease state. The inclusion and effective use of electronic PROs and ObsROs in AD and dementia was evaluated. The most commonly used outcomes measures in AD include: Clinical Dementia Rating (CDR) scale, Concord Informant Dementia Scale (CIDS), EuroQol 5-Dimension (EQ-5D), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), Health Utilities Index (HUI), Memory Impairment Screen (MIS), Short Form-36 (SF-36), and World Health Organization Quality of Life-Brief (WHO-QOL-BREF). The Mini-mental State Examination (MMSE) was the most widely used screening tool for cognitive impairment in dementia and often used as a comparator with other instruments. When administered by a caregiver, the health state valuation (HSV), EQ-5D and HUI were effective in tracking with disease state and/or QoL and successfully completed by subcategories of AD patients. Caregivers and the general public were able to distinguish major AD transitions. Some ObsROs did not accurately reflect subject QoL and/or health status. Electronic administration of outcomes measures were successfully used with AD and dementia patients and their caregivers. The CDR, CIDS, EQ-5D, HSV, HUI, IQCODE, MIS, and SF-36 are examples of questionnaires that were determined to be effective via electronic administration, demonstrating ease of use and/or reliability. PRO and ObsRO have been widely used with AD patients and their caregivers. Evidence shows that some of these measures are more congruent than others with the patient's disease state and/or QoL. There is great potential for outcomes measures and screening instruments to be administered electronically via patients and caregivers in AD and dementia.